Mechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk

Wen Hsi Lan; Ting Yu Lin; Jia Ai Yeh; Chun Lung Feng; Jun Te Hsu; Hwai Jeng Lin; Chia Jung Kuo; Chih Ho Lai

doi:10.3390/ijms232214163

Mechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk

Wen Hsi Lan, Ting Yu Lin, Jia Ai Yeh, Chun Lung Feng, Jun Te Hsu, Hwai Jeng Lin, Chia Jung Kuo, Chih Ho Lai

Research output: Contribution to journal › Review article › peer-review

10 Citations (Scopus)

Abstract

Diabetes mellitus is associated with a high risk of developing gastric cancer (GC). Metformin, which is conventionally used to treat type 2 diabetes, induces AMP-activated protein kinase signaling and suppresses gluconeogenesis. Recent studies have reported that metformin is associated with beneficial effects in cancer prevention and treatment owing to its anti-tumor effects. This makes metformin a potential medication for GC therapy. However, contradicting reports have emerged regarding the efficacy of metformin in reducing the risk of GC. This review summarizes the impact of metformin on mitigating GC risk by analyzing clinical databases. The mechanism underlying the anti-tumor effect of metformin on GC is also discussed.

Original language	English
Article number	14163
Journal	International journal of molecular sciences
Volume	23
Issue number	22
DOIs	https://doi.org/10.3390/ijms232214163
Publication status	Published - Nov 2022

Keywords

diabetes mellitus
gastric cancer
metformin
microbiota
reactive oxygen species

ASJC Scopus subject areas

Catalysis
Molecular Biology
Spectroscopy
Computer Science Applications
Physical and Theoretical Chemistry
Organic Chemistry
Inorganic Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/ijms232214163

Cite this

@article{d1b2b0e82aca4d849ce45a533ad813e1,

title = "Mechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk",

abstract = "Diabetes mellitus is associated with a high risk of developing gastric cancer (GC). Metformin, which is conventionally used to treat type 2 diabetes, induces AMP-activated protein kinase signaling and suppresses gluconeogenesis. Recent studies have reported that metformin is associated with beneficial effects in cancer prevention and treatment owing to its anti-tumor effects. This makes metformin a potential medication for GC therapy. However, contradicting reports have emerged regarding the efficacy of metformin in reducing the risk of GC. This review summarizes the impact of metformin on mitigating GC risk by analyzing clinical databases. The mechanism underlying the anti-tumor effect of metformin on GC is also discussed.",

keywords = "diabetes mellitus, gastric cancer, metformin, microbiota, reactive oxygen species",

author = "Lan, {Wen Hsi} and Lin, {Ting Yu} and Yeh, {Jia Ai} and Feng, {Chun Lung} and Hsu, {Jun Te} and Lin, {Hwai Jeng} and Kuo, {Chia Jung} and Lai, {Chih Ho}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",

year = "2022",

month = nov,

doi = "10.3390/ijms232214163",

language = "English",

volume = "23",

journal = "International journal of molecular sciences",

issn = "1661-6596",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "22",

}

TY - JOUR

T1 - Mechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk

AU - Lan, Wen Hsi

AU - Lin, Ting Yu

AU - Yeh, Jia Ai

AU - Feng, Chun Lung

AU - Hsu, Jun Te

AU - Lin, Hwai Jeng

AU - Kuo, Chia Jung

AU - Lai, Chih Ho

PY - 2022/11

Y1 - 2022/11

N2 - Diabetes mellitus is associated with a high risk of developing gastric cancer (GC). Metformin, which is conventionally used to treat type 2 diabetes, induces AMP-activated protein kinase signaling and suppresses gluconeogenesis. Recent studies have reported that metformin is associated with beneficial effects in cancer prevention and treatment owing to its anti-tumor effects. This makes metformin a potential medication for GC therapy. However, contradicting reports have emerged regarding the efficacy of metformin in reducing the risk of GC. This review summarizes the impact of metformin on mitigating GC risk by analyzing clinical databases. The mechanism underlying the anti-tumor effect of metformin on GC is also discussed.

AB - Diabetes mellitus is associated with a high risk of developing gastric cancer (GC). Metformin, which is conventionally used to treat type 2 diabetes, induces AMP-activated protein kinase signaling and suppresses gluconeogenesis. Recent studies have reported that metformin is associated with beneficial effects in cancer prevention and treatment owing to its anti-tumor effects. This makes metformin a potential medication for GC therapy. However, contradicting reports have emerged regarding the efficacy of metformin in reducing the risk of GC. This review summarizes the impact of metformin on mitigating GC risk by analyzing clinical databases. The mechanism underlying the anti-tumor effect of metformin on GC is also discussed.

KW - diabetes mellitus

KW - gastric cancer

KW - metformin

KW - microbiota

KW - reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=85142842385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142842385&partnerID=8YFLogxK

U2 - 10.3390/ijms232214163

DO - 10.3390/ijms232214163

M3 - Review article

C2 - 36430639

AN - SCOPUS:85142842385

SN - 1661-6596

VL - 23

JO - International journal of molecular sciences

JF - International journal of molecular sciences

IS - 22

M1 - 14163

ER -

Mechanism Underlying Metformin Action and Its Potential to Reduce Gastric Cancer Risk

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this